Objective:

To expand the indication for CAPVAXIVE for pediatric patients aged 2 to 17 years with chronic medical conditions that increase the risk of pneumococcal disease who have completed a primary pneumococcal vaccination series.

Approach:

Key Findings:

• CAPVAXIVE is indicated for the prevention of invasive pneumococcal disease in at-risk pediatric patients.
• Efficacy studies have not been conducted; estimates are based on epidemiological data rather than direct vaccine efficacy.
• Serious adverse events occurred in 5.5% of CAPVAXIVE recipients compared to 7.2% for the comparator vaccine.

Interpretation:

CAPVAXIVE is indicated in the US for patients aged 2 to 17 years with increased risk for pneumococcal disease.

Limitations:

• Efficacy studies have not been conducted for CAPVAXIVE.
• Estimates of coverage are based on epidemiological data rather than direct vaccine efficacy.

Conclusion:

CAPVAXIVE's indication expansion allows for prevention in a vulnerable pediatric population.

Sources:

• Merck & Co, Inc
Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.